BiopharmaTrend.com

Antiverse

Antiverse

Private company
ANTIVERSE

Antiverse is building a world-first computational antibody drug discovery platform to predict antibody-antigen binding and provide antibody drug candidates in one day.

A combination of state of the art machine learning and cell-free protein synthesis is used to predict antibodies that bind to a given antigen target with high affinity. The resulting software can then take antigen target sequence, provided by the customer, and do a high-throughput screening of all possibilities of antibody sequences to detect the sequence that will produce a high-affinity antibody for the target. The customer will be provided with the sequence in a single day, thus reducing the time typically required for antibody therapeutics discovery by 3 to 18 months.


Founded
2017
Status
Private company
Geography
United Kingdom based
Funding
$0.473 M

Products

No products posted yet

Services

No services posted yet


This data is part of our proprietary analytics report:

This service is currently only supported on the desktop screens, please, use this service from your desktop or laptop for correct visualization and functionality

Go to home page